The Gates Foundation will invest up to $50 million to support Tessera's SCD gene editing treatment, the company said.

More than 500,000 babies were tested for sickle cell disease in Catalonia’s newborn screening program, with 160 cases ...

The following is a summary of “Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

Researchers developed a novel calculator may help to tailor pain medication regimens to patients with SCD seeking emergency ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Dec. 18, 2024 — Scientists have generated human stem cell models which contain notochord -- a tissue in the developing embryo that acts like a navigation system, directing cells where to build ...

A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...

eLife is a non-profit organisation inspired by research funders and led by scientists. Our mission is to help scientists accelerate discovery by operating a platform for research communication that ...